What is medioresinol and what foods contain it?

Medioresinol is a plant lignan — a type of polyphenolic compound — found naturally in sesame seeds, flaxseed, rye bran, and certain medicinal herbs such as Forsythia and Eucommia ulmoides. Like other dietary lignans, it can be converted by gut microbiota into enterolignans such as enterodiol and enterolactone, which may contribute to its biological activity in the human body.

Does medioresinol protect the brain after a stroke?

In mouse models of ischemic stroke, medioresinol significantly reduced brain infarct volume and improved neurological deficit scores (PMID: 33915296), indicating meaningful neuroprotection. The mechanism involves reducing blood-brain barrier permeability and inhibiting endothelial pyroptosis via suppression of NLRP3 inflammasome and caspase-1 activation. No human stroke trials have been conducted, so these findings cannot yet be directly applied clinically.

How does medioresinol protect heart cells?

In cardiomyocyte cell cultures subjected to oxygen-glucose deprivation (OGD) — a model simulating ischemia-reperfusion injury — medioresinol enhanced cell viability and lowered oxidative stress markers including malondialdehyde (MDA) while boosting superoxide dismutase (SOD) activity (PMID: 39331625, PMC11433142). These effects suggest it protects mitochondrial function and reduces lipid peroxidation during cardiac ischemic events. All current cardioprotective evidence remains in vitro, and human data are lacking.

Is medioresinol safe to take as a supplement?

No human safety or toxicology trials for isolated medioresinol supplements have been published, making it impossible to establish a confirmed safe dosage range. Because it belongs to the phytoestrogen lignan class, individuals with hormone-sensitive conditions, those on estrogen-modulating medications like tamoxifen, or those who are pregnant or breastfeeding should avoid isolated supplementation. Consuming medioresinol through whole food sources such as sesame and flaxseed is considered safe within normal dietary amounts.

What is the difference between medioresinol and other lignans like secoisolariciresinol?

Medioresinol, secoisolariciresinol (SDG), and matairesinol are all plant lignans but differ structurally and in their biological activity profiles. Secoisolariciresinol from flaxseed is the most clinically studied lignan with human trials examining cardiovascular and breast cancer risk, while medioresinol research remains exclusively preclinical. Medioresinol appears particularly notable for neuroprotective and anti-pyroptotic mechanisms, whereas SDG is more associated with hormonal modulation and lipid metabolism.

What is the bioavailability of medioresinol and does it absorb better with food?

Medioresinol, like other lignans, requires conversion by gut microbiota to its active metabolites for absorption, which may be enhanced when consumed with dietary fat. Individual variation in gut bacterial composition can significantly affect bioavailability, meaning some people may convert and absorb medioresinol more efficiently than others. Consuming medioresinol-rich foods or supplements with meals that contain fat sources may optimize absorption compared to taking on an empty stomach.

Does medioresinol interact with blood pressure or cardiovascular medications?

Limited clinical data exists on medioresinol interactions with cardiovascular medications, though its PI3K/AKT pathway activation suggests potential additive effects with certain heart medications. Individuals taking blood pressure-lowering agents, antiplatelet drugs, or statins should consult a healthcare provider before supplementing with medioresinol, as combined effects on vascular function are not well characterized. Current evidence is primarily from animal models rather than human drug interaction studies.

How strong is the clinical evidence for medioresinol's neuroprotective effects in humans?

Current evidence for medioresinol's neuroprotection comes primarily from animal models, particularly mice studies showing reduced brain infarct volume and improved blood-brain barrier integrity following stroke. Human clinical trials investigating medioresinol for stroke recovery or cognitive protection have not been conducted, limiting the ability to confirm these benefits in patients. While the mechanistic research is promising, supplementation decisions should account for the lack of human efficacy data at this time.

Medioresinol

Medioresinol is a plant-derived lignan found in sesame, flaxseed, and various herbs that exerts neuroprotective and cardioprotective effects primarily through antioxidant and anti-inflammatory mechanisms. It reduces oxidative stress by scavenging reactive oxygen species and inhibiting pyroptotic cell death pathways, thereby protecting neurons and myocardial cells from ischemic injury.

Category: Compound Evidence: 2/10 Tier: Emerging

Origin & History

Medioresinol is a lignan found in plants like Eucommia ulmoides and Magnolia species. It is typically extracted using solvent-based methods designed for lignans.

Historical & Cultural Context

While medioresinol itself lacks historical use documentation, it is derived from Eucommia ulmoides bark, used in Traditional Chinese Medicine for cardiovascular conditions. The specific role of medioresinol in these treatments is a modern attribution.

Health Benefits

• Reduces brain infarct volume and improves neuroprotection in mice models (PMID: 33915296). • Enhances cell viability and reduces oxidative stress in myocardial cells under OGD conditions (PMID: 39331625, PMC11433142). • Decreases blood-brain barrier permeability and endothelial pyroptosis (PMID: 33915296). • Activates PI3K/AKT/mTOR pathway, reducing inflammation in myocardial cells (PMID: 39331625, PMC11433142). • Exhibits antifungal and antibacterial properties in microbial models.

How It Works

Medioresinol reduces neuronal and myocardial damage by suppressing NLRP3 inflammasome-mediated pyroptosis and decreasing gasdermin D cleavage, limiting inflammatory cell death in endothelial and cardiac cells. It scavenges reactive oxygen species (ROS) and upregulates endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase, reducing lipid peroxidation under oxygen-glucose deprivation (OGD) conditions. Additionally, it decreases blood-brain barrier permeability by preserving tight junction protein integrity, potentially through inhibition of NF-κB and caspase-1 signaling cascades.

Scientific Research

No human clinical trials or meta-analyses were identified. Available evidence is limited to preclinical studies, such as a mouse model of tMCAO and in vitro studies on myocardial cells (PMID: 33915296, PMID: 39331625, PMC11433142).

Clinical Summary

Current evidence for medioresinol is confined to preclinical animal and cell-based models, with no completed human clinical trials published to date. In murine ischemic stroke models, medioresinol administration significantly reduced brain infarct volume and improved neurological deficit scores (PMID: 33915296), demonstrating dose-dependent neuroprotection. In vitro studies using cardiomyocytes subjected to oxygen-glucose deprivation showed enhanced cell viability and reduced oxidative stress markers following medioresinol treatment (PMID: 39331625). The evidence base is promising but preliminary; extrapolation to human dosing and efficacy requires rigorous clinical investigation.

Nutritional Profile

Medioresinol is a pure lignan compound (a type of polyphenolic phytochemical), not a food ingredient with conventional macronutrient or micronutrient profiles. As an isolated bioactive compound, it does not contain proteins, carbohydrates, fats, vitamins, or dietary minerals in any nutritional sense. Chemically, it is a furofuran-type lignan with molecular formula C₂₁H₂₄O₇ and molecular weight approximately 392.41 g/mol. It is naturally found in trace concentrations in plant sources including sesame (Sesamum indicum), forsythia species, and various traditional medicinal herbs such as Eucommia ulmoides and Syringa species. Typical concentrations in plant sources range from 0.01–0.5 mg/g dry weight depending on the species and plant part. Bioavailability is characteristic of lignans generally: oral bioavailability is limited and variable due to poor aqueous solubility (lipophilic compound, logP estimated ~1.8–2.5), requiring gut microbiota metabolism for partial activation. Like other lignans, it may undergo enterohepatic circulation. No established dietary reference intake or recommended dose exists. Its biological activity is relevant at micromolar concentrations in experimental models (typically 10–100 µM in vitro). It is not classified as a nutrient; its relevance is strictly as a bioactive phytochemical with pharmacological properties.

Preparation & Dosage

Preclinical in vitro studies used dosages of 60 μM and 120 μM of pure medioresinol. No human dosages are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Eucommia ulmoides, Magnolia extract, PGC-1α activators, PI3K/AKT/mTOR pathway enhancers

Safety & Interactions

No human clinical safety trials for isolated medioresinol have been published, making a definitive side effect profile impossible to establish at this time. Because medioresinol is a phytoestrogen-class lignan, theoretical interactions with estrogen receptor-sensitive conditions (e.g., hormone-sensitive cancers) or estrogen-modulating medications such as tamoxifen cannot be excluded. Pregnant or breastfeeding individuals should avoid isolated medioresinol supplements due to the complete absence of safety data in these populations. Individuals on anticoagulant therapy or CYP450-metabolized drugs should exercise caution, as related lignans are known to influence drug-metabolizing enzymes.